Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Valeant Sells Pan-Asia Marketing Rights to Invida

publication date: Mar 3, 2008

Valeant Pharmaceuticals International (NYSE: VRX) will sell its Asia Pacific operations to Invida Pharmaceutical Holdings Pte. Ltd. for a one-time cash payment of $37.8 million. Invida will now be able to market a portfolio of 230 former Valeant products to 12 Asian countries, including Singapore, the Philippines, Taiwan, Korea, and China. Invida, which is located in Singapore, is a holding company whose divisions include Pharmalink, a pharmaceutical and healthcare commercialization provider in the Asia Pacific region, and Inovail, a pharma focused on dermatology, complementary oncology and female healthcare. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here